Exchange Bulletin
NetraMark Holdings Inc. (AIAI) To Trade On Toronto Stock Exchange
February 18, 2026
| Issuer: | NetraMark Holdings Inc. (the "Company") |
| Security: | Common shares |
| Symbol: | AIAI |
| Number of securities issued and outstanding: | 91,833,699 common shares |
| Number of securities reserved for issuance: | 16,781,406 common shares |
| Listing category: | Diversified |
| Trading currency: | CDN$ |
| Listing and posted for trading date: | February 18, 2026 (at the opening) |
| Other market(s): | The common shares have been listed on the Canadian Securities Exchange (the "CSE") since June 7, 2021 under the symbol "AIAI". TSX has been advised that the common shares will be delisted from the CSE on February 17, 2026 (at the close). |
| Temporary market maker: | Research Capital Corporation |
| Investor relations: | George Achilleos Chief Executive Officer (403) 701 – 1756 george@netramark.com - or - Swapan Kakumanu Chief Financial Officer (403) 681 – 2549 swapan@netramark.com |
| Incorporation: | Business Corporations Act (British Columbia) |
| Fiscal year end: | September 30 |
| Nature of business: | The Company is a Canadian artificial intelligence ("AI") technology company focused on AI-driven solutions for clinical trial optimization in the pharmaceutical and biotechnology industries. The Company's mission is to leverage novel machine learning techniques to address critical challenges in drug development, particularly the high failure rates of clinical trials due to patient heterogeneity and small sample sizes. |
| Transfer agent and registrar: | Odyssey Trust Company at its office in Toronto, Vancouver and Calgary. |
| Dividends: | No dividends have been paid and any determination to pay any future dividends will be at the discretion of the Board and will be made based on the Company's financial condition and other factors deemed relevant to the Board. |
| Sponsorship: | Research Capital Corporation |
| TSX contact: | Selma Thaver, Managing Director, TSX Listings |